|
Dan Hartman, MD |
|
Dr. Hartman brings extensive pharmaceutical development experience to GLDD. Dr. Hartman’s experience includes Senior Vice President for deCODE Genetics where he leads the company’s drug development efforts. Prior to joining deCODE he served for several years in senior clinical development positions at Pfizer, including Global Clinical Leader, Allergy and Respiratory Diseases; Clinical Exploratory Head, Cardiovascular and Metabolic Diseases; and Experimental Medicine Therapy Area Leader, Cardiovascular, Metabolism and Dermatology. From 2000 to 2002, Dr. Hartman was Vice President of Worldwide Clinical Development at Esperion Therapeutics where he co-authored a protocol with Dr. Steven Nissen the results of which led to the $1.3B acquisition of Esperion by Pfizer. Prior to joining Esperion, he was Director, Clinical Cardiovascular and Therapy Head, thrombosis and Cardiopulmonary Disease at Pfizer. From 1995 to 1999, Dr. Hartman served in senior clinical research positions at Eli Lilly & Company. Dr. Hartman received his MD from Wayne State University, held post-doctoral and faculty positions at the Indiana University School of Medicine. He completed board certification in internal medicine and is a member of numerous medical societies. He is the recipient of numerous awards including “Inventor of the Year” in 2002, awarded by the Intellectual Property Owners Association for a patent he co-authored and BIO-IT World international award for “computational biology and informatics” in 2005, an award shared with Dr. Hermann. |
